Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD – Get Rating) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 1,900 shares, a decrease of 57.8% from the August 15th total of 4,500 shares. Based on an average trading volume of 43,500 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Intelligent Medicine Acquisition

Hedge funds have recently bought and sold shares of the business. Centiva Capital LP increased its holdings in shares of Intelligent Medicine Acquisition by 45.6% during the 2nd quarter. Centiva Capital LP now owns 43,535 shares of the company's stock worth $436,000 after buying an additional 13,644 shares during the last quarter. Aristeia Capital LLC increased its holdings in shares of Intelligent Medicine Acquisition by 67.6% during the 2nd quarter. Aristeia Capital LLC now owns 419,000 shares of the company's stock worth $4,198,000 after buying an additional 169,000 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Intelligent Medicine Acquisition by 14.6% during the 2nd quarter. Woodline Partners LP now owns 28,650 shares of the company's stock worth $287,000 after buying an additional 3,650 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Intelligent Medicine Acquisition by 2.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 439,530 shares of the company's stock worth $4,404,000 after buying an additional 12,288 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Intelligent Medicine Acquisition during the 2nd quarter worth approximately $2,647,000. Institutional investors and hedge funds own 55.04% of the company's stock.

Intelligent Medicine Acquisition Stock Performance

IQMD stock remained flat at $10.04 during mid-day trading on Wednesday. 2,747 shares of the company's stock were exchanged, compared to its average volume of 41,796. Intelligent Medicine Acquisition has a 12 month low of $9.86 and a 12 month high of $10.93. The company's fifty day moving average price is $10.04 and its 200 day moving average price is $10.01.

Intelligent Medicine Acquisition Company Profile

Intelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science.

See Also

• Get a free copy of the StockNews.com research report on Intelligent Medicine Acquisition (IQMD)
• Is Lyft Going To Make It As Acquisition Rumors Swirl?
• Can Health Drink Maker Celsius Outrun Its Monster Rival?
• It's Time To Embrace Another 25% Decline In The S&P 500
• Four Cheap Stocks With Interesting Insider Activity
• Is Five Below Trying to Punch Too High?

Receive News & Ratings for Intelligent Medicine Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Medicine Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.